On April 26, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present pre-clinical data on its lead pre-clinical asset COM503 in an oral presentation at the 20th CIMT (Free CIMT Whitepaper) annual meeting, Europe’s Cancer Immunotherapy Meeting, on May 3-5, 2023, in Mainz, Germany (Press release, Compugen, APR 26, 2023, https://www.prnewswire.com/news-releases/compugen-to-present-data-on-its-lead-pre-clinical-asset-com503-in-an-oral-presentation-at-the-20th-cimt-annual-meeting-301805591.html [SID1234630570]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very excited to be presenting our pre-clinical data on COM503, a novel approach to harness cytokine biology to treat cancer, discovered using our proprietary computational discovery platform," said Eran Ophir, Ph.D., SVP Research and Drug Discovery at Compugen. "The inflammasome derived cytokine IL-18 is abundantly expressed in the tumor microenvironment (TME) but is blocked naturally by IL-18 binding protein, thereby preventing IL-18 from activating NK and T cells and its resulting anti-tumor activity. During our oral presentation at CIMT (Free CIMT Whitepaper) we will present pre-clinical data showing that COM503 binds with high affinity to IL-18 binding protein, freeing IL-18 and restoring NK and T cell activity. We will also show that blocking IL-18 binding protein prevents tumor growth and releases IL-18 to activate immunity in the TME without affecting peripheral immunity in murine tumor models. This is a differentiated approach to harness cytokine biology for cancer therapeutics. IL-18 is one of the rare cytokines which is naturally blocked by an endogenous binding protein, presenting a potentially unique opportunity to use a blocking antibody to release IL-18 at the site where it is needed to fight cancer, thereby potentially overcoming the limitations of systemically administered cytokines."
Presentation details:
Abstract number: 213
Title: Unleashing natural IL18 activity using an anti-IL18BP blocker antibody induces potent immune stimulation and anti-tumor activity
First Author: Menachem, A
Poster presentation: Thursday, May 4, 2023
Oral presentation: Friday, May 5, 2023
Presenter: Ophir, E
The abstract is available on the publication section of Compugen’s website at www.cgen.com. The poster and presentation will be made available on the publication section of Compugen’s website at www.cgen.com following presentation.